Select Page

ai

Multi-Analyte Liquid Biopsy

At Oncophenomics, we’re leading the way in personalized cancer care with our state-of-the-art liquid biopsy tests. Our innovative approach allows for early detection, personalized treatment selection, monitoring for minimal residual disease, and overcoming drug resistance.

What we Do

Early Detection

At Oncophenomics, we’re leading the way in personalized medicine, improving patient outcomes through our cutting-edge liquid biopsy tests. Our innovative approach allows for early detection and personalized treatment selection, unlocking the potential of PARP inhibitors, monitoring minimal residual disease (MRD), and overcoming drug resistance.

N

Enabling Personalized Treatment

N

Improve Clinical Outcomes

N

Monitor Response to Treatment

Comprehensive

Genomic Profiling for both tissue and liquid biopsy enables us to custom-tailor the treatments unique to each patient

GPU for Genomics

We have built both cloud and offline servers customized for handling large genomics datasets

Machine Learning

Algorithms to query custom large language inference models (Variant-GPT, Bio-GPT) for clinical interpretation of key genomic findings

Bioinformatics

Custom Bioinformatics Data Analysis Pipelines built with Nextflow form the core of our technology. Fully automated streamlined Raw data to Reports

R&D

Research & Development

Our state-of-the-art liquid biopsy tests enable early detection of cancer, providing unprecedented insights into the disease. By analyzing circulating tumor DNA, we can identify genetic alterations and monitor treatment response, allowing for personalized treatment selection.

N

Revolutionizing Cancer Diagnostics

N

Unleashing the Potential of Liquid Biopsy

N

Detecting Minimal Residual Disease

Clients

We work with Biotech, Biopharma, Cancer Hospitals & Oncologists

Discover the power of comprehensive genomic profiling and its ability to revolutionize targeted therapies. Our state-of-the-art liquid biopsy tests provide invaluable insights for personalized treatment selection.

N

Paitent Selection for Clinical Trials

N

Biomarkers as End Points

N

Clinical & Translational Cancer Research

Have a custom project?

By leveraging our multi-omics multi-analyte liquid biopsy technology we can support multiple use cases from discovery to clinical stage

Browse existing case studies and products

Coming soon…

Company

Suite 104, 1st Floor, Inspire Infra-Horizon, Future Kids School Road, Financial District, Nanakramguda, Hyderabad, Telangana-500032

Contact

[email protected]

+91-8886233344